Imperative Care
Imperative Care develops and manufactures FDA-cleared access and aspiration thrombectomy catheters (Zoom stroke system, Symphony for DVT/PE, Prodigy for peripheral occlusion). It also develops Telos endovascular robotics and Kandu stroke-recovery technology. It sells to hospitals and neurointerventional and vascular physicians. The company is venture-backed and has raised about $600M in total, including a $260M Series D in 2021, a Series E in 2024 and a $100M convertible note in 2026. Third-party sources estimate 2025 revenue at about $162M (unverified), and headcount is roughly 420 as of mid-2026.
Funding
Every round, secondary, debt facility or acquisition involving Imperative Care that AI Lounge tracks, newest first.
No rounds recorded yet.
Members see every AI company on AI Lounge with revenue, funding, valuation and investors, searchable and sortable, free.
Create my free account →Log in